Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR-T Cell Therapy

Recommended

Association of Geriatric Measures and Global Frailty With Cognitive Decline After Allogeneic Hematopoietic Cell Transplantation in Older Adults

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR-T Cell Therapy

header-info

Sep, 18, 2023

New study results demonstrated that CAR-HEMATOTOX scores are valuable in predicting treatment outcomes and toxicity risks among patients with relapsed/refractory mantle cell lymphoma.

Access the full article to read more here.